Company / Cash & Equivalents
Adaptive Biotechnologies Corp Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$70.5M
FY2025
5-year range
$47.9M / $139.1M
FY2021-FY2025
Trend
+47.1%
vs FY2024
Sector context
#165 of 207
Health Care
What the data says
Adaptive Biotechnologies Corp's cash & equivalents of $70M is lower than 80% of companies in the Health Care sector (FY2025). Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $70M.
Based on SEC 10-K filings.
$70M in FY2025 with a 5-year CAGR of -10.6%.
Improved from $65M to $70M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -7.8%
- 5-Year CAGR
- -10.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 207This company $70.5M Sector average $669.5M
▼
-89.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -10.6%, indicating a declining trend.
- In FY2025, cash & equivalents increased 47.1% year-over-year.
- Ranks #165 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.45 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $70.5M | +47.1% |
| FY2024 | $47.9M | -26.3% |
| FY2023 | $65.1M | -27.7% |
| FY2022 | $90.0M | -35.3% |
| FY2021 | $139.1M | +12.7% |
| FY2020 | $123.4M | +27.8% |
| FY2019 | $96.6M | +75.5% |
| FY2018 | $55.0M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026